FMBA has filed documents for registration of the medicine for coronavirus "MIR-19"

In RUSSIA, the second phase of research on the inhaled medicine for CORONAVIRUS MIR-19 has been completed, the developers have submitted documents for registration of the drug. The operational headquarters announced this in TELEGRAM.

“It is expected that the [registration] process will be completed no later than December of this year,” the report said.

The drug was developed by the Institute of Immunology of the Federal Medical and Biological Agency (FMBA). The drug acts on the principle of etiotropic therapy, that is, against the causative agent of the disease. The drug affects a specific section of the virus genome and does not allow it to multiply. “No side effects were found in the drug,” the headquarters assured.

The drug "MIR-19" received a patent in early April, its name stands for "Small Interfering RNA". According to the plans of the developers, the medicine can be used as a nasal spray and liquid for inhalation. According to Veronika Skvortsova, HEAD of the FMBA, MIR-19 is a unique medicine that does not affect the human genome and immunity, but “turns off” copying of the coronavirus with great efficiency.